United Therapeutics (NASDAQ:UTHR) CEO Sells $5,365,695.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction on Friday, April 24th. The stock was sold at an average price of $564.81, for a total value of $5,365,695.00. Following the transaction, the chief executive officer owned 40,513 shares of the company’s stock, valued at approximately $22,882,147.53. This represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

United Therapeutics Stock Performance

Shares of UTHR traded down $0.17 during midday trading on Monday, hitting $566.99. 242,375 shares of the stock were exchanged, compared to its average volume of 488,391. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $607.89. The stock has a fifty day simple moving average of $536.51 and a 200 day simple moving average of $494.61. The firm has a market cap of $24.85 billion, a P/E ratio of 20.32, a P/E/G ratio of 1.61 and a beta of 0.75.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping the consensus estimate of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. During the same period last year, the business posted $6.19 earnings per share. The company’s quarterly revenue was up 7.4% on a year-over-year basis. As a group, equities research analysts forecast that United Therapeutics Corporation will post 27.97 EPS for the current fiscal year.

Institutional Trading of United Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of UTHR. Wellington Management Group LLP raised its stake in United Therapeutics by 74.5% in the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after buying an additional 1,042,711 shares in the last quarter. Darwin Global Management Ltd. acquired a new stake in United Therapeutics in the third quarter valued at $317,617,000. Norges Bank acquired a new stake in United Therapeutics in the fourth quarter valued at $293,418,000. Avoro Capital Advisors LLC raised its stake in United Therapeutics by 17.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after buying an additional 383,838 shares in the last quarter. Finally, Janus Henderson Group PLC raised its stake in United Therapeutics by 75.1% in the fourth quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock valued at $387,801,000 after buying an additional 341,383 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on UTHR. HC Wainwright lifted their target price on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a report on Tuesday, March 31st. Royal Bank Of Canada lifted their target price on United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Finally, UBS Group lifted their target price on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a report on Thursday, March 5th. Ten analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $601.50.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.